Pliant Therapeutics financials
$1.080.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$23.9M | -$21.8M | -$23.6M | -$28.3M | -$45.6M | -$58.9M | -$53.3M | -$62.0M | -$60.6M | -$52.4M | -$47.0M | -$47.7M |
| Net income | -$22.4M | -$20.0M | -$23.6M | -$26.3M | -$43.3M | -$56.2M | -$49.7M | -$57.8M | -$55.9M | -$47.0M | -$41.1M | -$41.5M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.36 | $-0.32 | $-0.38 | $-0.43 | $-0.71 | $-0.92 | $-0.82 | $-0.95 | $-0.92 | $-0.78 | $-0.69 | $-0.70 |
| EBITDA | -$23.6M | -$21.5M | -$23.2M | -$27.8M | -$45.1M | -$58.5M | -$52.9M | -$61.5M | -$60.0M | -$51.9M | -$46.6M | -$47.2M |
| Operating cash flow | -$12.8M | -$19.2M | -$17.8M | -$21.1M | -$40.6M | -$48.9M | -$47.7M | -$32.3M | -$45.3M | -$30.3M | -$25.1M | -$36.2M |
| Free cash flow | -$12.8M | -$19.2M | -$17.8M | -$21.1M | -$40.7M | -$49.1M | -$47.9M | -$33.2M | -$46.5M | -$31.8M | -$25.2M | -$36.3M |
| Diluted shares | 61.9M | 61.8M | 61.5M | 61.4M | 61.4M | 61.2M | 60.9M | 60.7M | 60.4M | 60.2M | 60.0M | 59.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $24.9M | $22.2M | $45.4M | $93.7M | $86.8M | $91.9M |
| Short-term investments | $133.2M | $148.7M | $145.5M | $148.1M | $176.1M | $213.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $30.4M | $30.4M | $30.3M |
| Total assets | $189.9M | $202.6M | $225.2M | $276.6M | $299.8M | $344.8M |
| Total liabilities | $43.0M | $37.4M | $44.0M | $76.3M | $79.7M | $87.6M |
| Shareholders' equity | $146.9M | $165.2M | $181.2M | $200.3M | $220.1M | $257.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology